Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-Marketing Surveillance of Humira Injection in Korean Patients Under the "New-Drug Re-examination"

Next Previous
Search
Trial Profile

Post-Marketing Surveillance of Humira Injection in Korean Patients Under the "New-Drug Re-examination"

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories

    • Most Recent Events

    • 13 Aug 2012 Actual end date (1 Jun 2012)added as reported by ClinicalTrials.gov record.
    • 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 May 2012 Planned end date changed from 1 Jul 2012 to 1 May 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top